Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab for Prevention of Lung Function Decline in Uncontrolled Moderate to Severe Asthma
NCT05097287Phase 4Active, not recruiting
- Sponsor
- Sanofi
- Start
- Dec 2021
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 23
01
Overview
A Phase 4 trial of dupilumab in asthma, sponsored by Sanofi. Started Dec 2021; status: active, not recruiting.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05097287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05097287.